Lack of correlation between PK and changes in pulmonary artery systolic pressure in healthy volunteers following administration of the HIF-prolyl hydroxylase inhibitor, GSK1278863.

被引：0

|

作者：

Demopoulos, Laura ^{[1
]}

Mahar, K. ^{[1
]}

Haws, T. F. ^{[1
]}

Morgan, L. A. ^{[1
]}

Fang, Z. ^{[1
]}

Olson, Eric J. ^{[1
]}

Lepore, J. J. ^{[1
]}

机构：

[1] GlaxoSmithKline, Heart Failure DPU, King Of Prussia, PA USA

来源：

PHARMACOTHERAPY | 2014年 / 34卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

175

引用

收藏

页码：E222 / E222

页数：1

相关论文

共 2 条

[1] Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects
Hara, Katsutoshi
Takahashi, Naoki
Wakamatsu, Akira
Caltabiano, Stephen
[J]. DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (06) : 410 - 418
[2] Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease
Olson, Eric
Demopoulos, Laura
Haws, Thomas F.
Hu, Erding
Fang, Zixing
Mahar, Kelly M.
Qin, Pu
Lepore, John
Bauer, Timothy A.
Hiatt, William R.
[J]. VASCULAR MEDICINE, 2014, 19 (06) : 473 - 482